journal article·2024-04Open access

A NRF2 Regulated and the Immunosuppressive Microenvironment Reversed Nanoplatform for Cholangiocarcinoma Photodynamic‐Gas Therapy

Weimin Wang, Yang Gao, Jianjun Xu, Tianhao Zou, Bin Yang, Shaobo Hu, Xiang Cheng, Yun Xia, Qichang Zheng

Advanced Science· Volume 11· Issue 14

Abstract

Abstract Photodynamic therapy (PDT) is a minimally invasive and controllable local cancer treatment for cholangiocarcinoma (CCA). However, the efficacy of PDT is hindered by intratumoral hypoxia and the presence of an antioxidant microenvironment. To address these limitations, combining PDT with gas therapy may be a promising strategy to enhance tumor oxygenation. Moreover, the augmentation of oxidative damage induced by PDT and gas therapy can be achieved by inhibiting NRF2, a core regulatory molecule involved in the antioxidant response. In this study, an integrated nanotherapeutic platform called CMArg@Lip, incorporating PDT and gas therapies using ROS‐responsive liposomes encapsulating the photosensitizer Ce6, the NO gas‐generating agent L‐arginine, and the NRF2 inhibitor ML385, is successfully developed. The utilization of CMArg@Lip effectively deals with challenges posed by tumor hypoxia and antioxidant microenvironment, resulting in elevated levels of oxidative damage and subsequent induction of ferroptosis in CCA. Additionally, these findings suggest that CMArg@Lip exhibits notable immunomodulatory effects, including the promotion of immunogenic cell death and facilitation of dendritic cell maturation. Furthermore, it contributes to the anti‐tumor function of cytotoxic T lymphocytes through the downregulation of PD‐L1 expression in tumor cells and the activation of the STING signaling pathway in myeloid‐derived suppressor cells, thereby reprogramming the immunosuppressive microenvironment via various mechanisms.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ferroptosis and cancer prognosis · Bladder and Urothelial Cancer Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hepatobiliary Surgery Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Liver Transplant Center Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Department of Digestive Oncology Surgery Cancer Centre Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Department of General Surgery Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China

Funding

National Natural Science Foundation of China

References (55)

Show source-provided references
1. 10.1002/smll.20200674210.1002/smll.202006742 ↗
2. 10.1016/j.biomaterials.2020.11982710.1016/j.biomaterials.2020.119827 ↗
3. 10.1158/0008-5472.CAN-21-412210.1158/0008-5472.CAN-21-4122 ↗
4. 10.3390/cancers1313333610.3390/cancers13133336 ↗
5. 10.1016/j.pdpdt.2022.10271210.1016/j.pdpdt.2022.102712 ↗
6. 10.3390/cancers1514368610.3390/cancers15143686 ↗
7. 10.7150/thno.7246510.7150/thno.72465 ↗
8. 10.7150/thno.6730010.7150/thno.67300 ↗
9. 10.1186/s12951-023-02013-y10.1186/s12951-023-02013-y ↗
10. 10.1016/j.addr.2022.11434410.1016/j.addr.2022.114344 ↗
11. 10.1021/acsnano.9b0721210.1021/acsnano.9b07212 ↗
12. 10.1016/j.biomaterials.2022.12143310.1016/j.biomaterials.2022.121433 ↗
13. 10.1136/jitc-2020-00192610.1136/jitc-2020-001926 ↗
14. 10.1016/j.ajps.2023.10077510.1016/j.ajps.2023.100775 ↗
15. 10.1021/acs.nanolett.2c0298310.1021/acs.nanolett.2c02983 ↗
16. 10.7150/thno.7356610.7150/thno.73566 ↗
17. 10.1186/s12951-022-01617-010.1186/s12951-022-01617-0 ↗
18. 10.1002/adhm.20210077010.1002/adhm.202100770 ↗
19. 10.1016/j.jconrel.2022.11.00410.1016/j.jconrel.2022.11.004 ↗
20. 10.1021/acsami.0c2174310.1021/acsami.0c21743 ↗
21. 10.1016/j.cmet.2023.01.01210.1016/j.cmet.2023.01.012 ↗
22. 10.7150/thno.7724310.7150/thno.77243 ↗
23. 10.1158/2159-8290.CD-21-092210.1158/2159-8290.CD-21-0922 ↗
24. 10.1016/j.biomaterials.2023.12206810.1016/j.biomaterials.2023.122068 ↗
25. 10.1021/acsami.1c2286110.1021/acsami.1c22861 ↗
26. 10.1002/smll.20220698110.1002/smll.202206981 ↗
27. 10.1038/s41388-018-0314-010.1038/s41388-018-0314-0 ↗
28. 10.1002/advs.20220666910.1002/advs.202206669 ↗
29. 10.1016/j.immuni.2021.04.00410.1016/j.immuni.2021.04.004 ↗
30. 10.1016/j.immuni.2020.03.00410.1016/j.immuni.2020.03.004 ↗
31. 10.1158/0008-5472.CAN-22-190310.1158/0008-5472.CAN-22-1903 ↗
32. 10.1186/s12951-021-01078-x10.1186/s12951-021-01078-x ↗
33. 10.1016/j.jconrel.2023.07.01510.1016/j.jconrel.2023.07.015 ↗
34. 10.1016/j.biomaterials.2022.12144810.1016/j.biomaterials.2022.121448 ↗
35. Mohapatra A. · ACS Appl. Mater. Interfaces · 2023 · 15
36. 10.1016/j.jconrel.2022.12.03010.1016/j.jconrel.2022.12.030 ↗
37. 10.1021/acsami.2c1009810.1021/acsami.2c10098 ↗
38. 10.1016/j.jconrel.2023.01.00710.1016/j.jconrel.2023.01.007 ↗
39. 10.1016/j.redox.2022.10238910.1016/j.redox.2022.102389 ↗
40. 10.1016/j.addr.2021.11385110.1016/j.addr.2021.113851 ↗
41. 10.1002/advs.20210087610.1002/advs.202100876 ↗
42. 10.1016/j.plipres.2020.10105210.1016/j.plipres.2020.101052 ↗
43. 10.1016/j.redox.2021.10195010.1016/j.redox.2021.101950 ↗
44. 10.1038/s41418-022-00990-510.1038/s41418-022-00990-5 ↗
45. 10.1016/j.cmet.2020.12.00710.1016/j.cmet.2020.12.007 ↗
46. 10.7150/thno.6793210.7150/thno.67932 ↗
47. 10.1016/j.biomaterials.2022.12183210.1016/j.biomaterials.2022.121832 ↗
48. 10.1038/s41419-022-04851-410.1038/s41419-022-04851-4 ↗
49. 10.1016/j.biomaterials.2023.12205610.1016/j.biomaterials.2023.122056 ↗
50. 10.1002/cac2.1225010.1002/cac2.12250 ↗
51. 10.1016/j.molcel.2022.03.02210.1016/j.molcel.2022.03.022 ↗
52. 10.1016/j.semcancer.2022.07.00710.1016/j.semcancer.2022.07.007 ↗
53. 10.1186/s12951-021-01101-110.1186/s12951-021-01101-1 ↗
54. 10.7150/thno.8009110.7150/thno.80091 ↗
55. 10.1002/advs.20200274610.1002/advs.202002746 ↗